Grant Number:	5R01CA087486-04 Interpret this number
Primary Investigator:	Davis, Ronald
Organization:	Michigan Public Health Institute
Project Title:	Analysis of Tobacco Depositions and Trial Testimony
Fiscal Year:	2003

DESCRIPTION: (Applicant's Description) This project will analyze the depositions and trial testimony for tobacco lawsuits filed in the United States during the 1990s, to assess what they reveal in areas such as nicotine addiction and pharmacology, the health consequences of tobacco use, tobacco-product design and manufacturing, tobacco advertising and promotion, youth smoking initiation, and tobacco use cessation. The litigation documents to be studied will include those from the following lawsuits: 1) the state Attorney General (AG) cases (and similar cases filed by counties and cities); 2) the class actions (e.g., Castano cases, Broin, Engle), 3) the individual health-effects cases, 4) third-party reimbursement cases patterned after the AG cases (e.g., those filed by union-managed health and welfare funds and Blue Cross Blue Shield plans); and 5) other, miscellaneous cases (e.g., secondhand-smoke cases, Mangini case, cigarette fire damage suits, litigation involving federal agencies [e.g., the FDA and the U.S. EPA], and international/foreign claims filed in U.S. courts). Transcripts (and related exhibits) will be collected for the depositions and trials from law firms, courts, court reporters and their transcription firms, individual witnesses, and any other available sources. They will be formatted, coded, and made available on the World Wide Web in an easily searchable database called the Tobacco Deposition and Trial Testimony Archive (Tobacco DATTA). Eleven research teams will analyze the material in Tobacco DATTA in different topical areas, using qualitative and quantitative methods. The outcomes of the project will be: 1) the creation of a new, rich, accessible, user-friendly database pertaining to tobacco industry documents, research, knowledge, conduct, and strategies; and 2) research articles and reports, based on study of that database, concerning many important aspects of tobacco and health.




Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms.
Authors: Durham B.H. , Hershkovitz-Rokah O. , Abdel-Wahab O. , Yabe M. , Chung Y.R. , Itchaki G. , Ben-Sasson M. , Asher-Guz V.A. , Groshar D. , Doe-Tetteh S.A. , et al. .
Source: Blood Advances, 2023-12-12 00:00:00.0; 7(23), p. 7319-7328.
PMID: 37874915
Related Citations

Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Authors: Zhao Y. , Murciano-Goroff Y.R. , Xue J.Y. , Ang A. , Lucas J. , Mai T.T. , Da Cruz Paula A.F. , Saiki A.Y. , Mohn D. , Achanta P. , et al. .
Source: Nature, 2021 11; 599(7886), p. 679-683.
EPub date: 2021-11-10 00:00:00.0.
PMID: 34759319
Related Citations

The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
Authors: Müller C. , Obermann W. , Karl N. , Wendel H.G. , Taroncher-Oldenburg G. , Pleschka S. , Hartmann R.K. , Grünweller A. , Ziebuhr J. .
Source: Antiviral Research, 2021 02; 186, p. 105012.
EPub date: 2021-01-08 00:00:00.0.
PMID: 33422611
Related Citations

Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group.
Authors: Mulder R.L. , Hudson M.M. , Bhatia S. , Landier W. , Levitt G. , Constine L.S. , Wallace W.H. , van Leeuwen F.E. , Ronckers C.M. , Henderson T.O. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2020-12-10 00:00:00.0; 38(35), p. 4194-4207.
EPub date: 2020-09-29 00:00:00.0.
PMID: 33078972
Related Citations

British American Tobacco ghost-wrote reports on tobacco advertising bans by the International Advertising Association and J J Boddewyn.
Authors: Davis R.M. .
Source: Tobacco Control, 2008 Jun; 17(3), p. 211-4.
PMID: 18339800
Related Citations

Historians' testimony on "common knowledge" of the risks of tobacco use: a review and analysis of experts testifying on behalf of cigarette manufacturers in civil litigation.
Authors: Kyriakoudes L.M. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv107-16.
PMID: 17130618
Related Citations

Tobacco manufacturers' defence against plaintiffs' claims of cancer causation: throwing mud at the wall and hoping some of it will stick.
Authors: Milberger S. , Davis R.M. , Douglas C.E. , Beasley J.K. , Burns D. , Houston T. , Shopland D. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv17-26.
PMID: 17130620
Related Citations

Tobacco industry litigation position on addiction: continued dependence on past views.
Authors: Henningfield J.E. , Rose C.A. , Zeller M. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv27-36.
PMID: 17130621
Related Citations

How the health belief model helps the tobacco industry: individuals, choice, and "information".
Authors: Balbach E.D. , Smith E.A. , Malone R.E. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv37-43.
PMID: 17130622
Related Citations

The Tobacco Deposition and Trial Testimony Archive (DATTA) project: origins, aims, and methods.
Authors: Davis R.M. , Douglas C.E. , Beasley J.K. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv4-8.
PMID: 17130623
Related Citations

"Stay away from them until you're old enough to make a decision": tobacco company testimony about youth smoking initiation.
Authors: Wakefield M. , McLeod K. , Perry C.L. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv44-53.
PMID: 17130624
Related Citations

The role of tobacco advertising and promotion: themes employed in litigation by tobacco industry witnesses.
Authors: Goldberg M.E. , Davis R.M. , O'Keefe A.M. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv54-67.
PMID: 17130625
Related Citations

Challenging the epidemiologic evidence on passive smoking: tactics of tobacco industry expert witnesses.
Authors: Francis J.A. , Shea A.K. , Samet J.M. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv68-76.
PMID: 17130626
Related Citations

Economics on trial: the use and abuse of economic methods in third party tobacco litigation.
Authors: Max W. , Tsoukalas T. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv77-83.
PMID: 17130627
Related Citations

Consumer acceptable risk: how cigarette companies have responded to accusations that their products are defective.
Authors: Cummings K.M. , Brown A. , Douglas C.E. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv84-9.
PMID: 17130628
Related Citations

Epidemiology of the third wave of tobacco litigation in the United States, 1994-2005.
Authors: Douglas C.E. , Davis R.M. , Beasley J.K. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv9-16.
PMID: 17130629
Related Citations

Potential reduced exposure products (PREPs) in industry trial testimony.
Authors: Wayne G.F. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv90-7.
PMID: 17130630
Related Citations

Perceptions of industry responsibility and tobacco control policy by US tobacco company executives in trial testimony.
Authors: Chaiton M. , Ferrence R. , LeGresley E. .
Source: Tobacco Control, 2006 Dec; 15 Suppl 4, p. iv98-106.
PMID: 17130631
Related Citations